argenx SE (ARGX)
ARGX · Health Care · 
Belgium
argenx SE (ARGX) is a Belgian company in the Health Care sector. The stock has its largest weight in XESX (Euro STOXX 50), at 1.14%. Anyone who holds an ETF containing argenx also has an indirect stake in the company.
Data and Charts: argenx
Key Data for argenx
argenx Stock Price Chart
The argenx chart shows daily closing prices and is set to the current year by default. The stock is up 6.2% year to date and up 8.8% over twelve months. The last recorded close on October 30, 2026, was $892.87, at 58% of the 52-week range.
The chart shows the US listing in US dollars. On the home exchange the price can differ, since the currency and trading hours are different. For depositary receipts (ADRs), one receipt is not always one share.
Price series from our database since Sep 23, 2024, 529 daily values.
argenx Stock Performance
| Year to date | +6.2% | 1 year | +8.8% |
|---|---|---|---|
| 1 month | -6.9% | 3 months | +4.6% |
| Calendar year 2025 | +36.7% |
Measured in euros, argenx is up 11.7% year to date and up 12.5% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: argenx
argenx Connections
The map shows how argenx connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- Belgium Country · domicile
- Health Care Sector · sector
- Financiere de Tubize S.A. Stock · similar ETF exposure
- UCB S.A. Stock · similar ETF exposure
What ETF Is argenx In?
argenx has very high ETF coverage and is held by 29 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 97.7% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XESC / XESX | Euro STOXX 50 | 1.14% | €11.38 |
| ZPRE | MSCI EMU | 0.77% | €7.74 |
| XD5E | MSCI EMU | 0.77% | €7.71 |
| XEMU | MSCI EMU | 0.77% | €7.71 |
| SPFS | MSCI World Health Care | 0.62% | €6.19 |
| XDWH | MSCI World Health Care | 0.62% | €6.19 |
| XDEB | MSCI World Minimum Volatility | 0.59% | €5.94 |
| IMEA | MSCI Europe | 0.41% | €4.10 |
| SPYE | MSCI Europe | 0.41% | €4.08 |
| XMEU / XIEE | MSCI Europe | 0.41% | €4.07 |
| EXSA | STOXX Europe 600 | 0.38% | €3.80 |
| X600 / XESU | STOXX Europe 600 | 0.38% | €3.78 |
| XSX6 / XSX7 | STOXX Europe 600 | 0.37% | €3.71 |
| EXUS / EXU1 | MSCI World ex USA | 0.23% | €2.28 |
| SPYI / SPSA | MSCI ACWI IMI | 0.09% | €0.90 |
| XDWD / XDWL | MSCI World | 0.06% | €0.61 |
| EUNL | MSCI World | 0.06% | €0.60 |
| IUSQ | MSCI ACWI | 0.06% | €0.60 |
| SWWD | MSCI World | 0.06% | €0.57 |
| SPPW | MSCI World | 0.06% | €0.57 |
| SPYY | MSCI ACWI | 0.06% | €0.55 |
| WIMI | MSCI World IMI | 0.05% | €0.54 |
The last column shows how much of €1,000 in one of these funds goes to argenx, based on each fund's latest holdings list.
US-listed ETFs holding argenx (weight per latest SEC filing): VXUS 0.12%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
argenx Weight in iShares STOXX Europe 600 (EXSA) Since 2019
In iShares STOXX Europe 600 (EXSA), argenx had a weight of 0.05% on Sep 30, 2019 and 0.38% on Oct 29, 2026. The fund tracks the STOXX Europe 600. Its share peaked at 0.40% on Sep 30, 2026. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much argenx overlaps with the rest of a portfolio.
Stocks With ETF Exposure Similar to argenx
| Stock | Shared ETFs | r |
|---|---|---|
| argenx | – | – |
| Financiere de Tubize S.A. | 26 | – |
 UCB S.A. | 26 | – |
| Abivax | 26 | – |
| Sartorius Stedim Biotech | 26 | – |
| Eurofins Scientific | 26 | – |
| Sartorius Pref | 26 | – |
| Biomerieux | 26 | – |
| Orion | 26 | – |
These stocks reach a portfolio through largely the same funds as argenx. “Shared ETFs” counts the funds that hold both.
Fundamental Analysis: argenx
Latest Patents Granted to argenx
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, argenx received 3 utility patents. That is 0.001% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 3.5 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12774348 B2 | FcRn/antigen-binding molecules and methods of use | C07K Chemistry; metallurgy | ||
| US 12708664 B2 | Methods of treating paraproteinemic neuropathy with anti-C2 antibodies | A61K Human necessities | ||
| US 12565538 | FCRN/antigen-binding molecules and methods of use | – | C07K Chemistry; metallurgy |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: argenx BV. Titles as published by the office; median time based on 2 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
Technical Analysis: argenx
argenx Risk Metrics
The close on Oct 30, 2026, was 15.7% below the highest close since Sep 23, 2024. That high was reached on Aug 27, 2026. When the S&P 500 rose or fell 1%, argenx moved 0.39% on average in the same direction (past 252 trading days). The correlation of 0.13, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of argenx.
What argenx Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Revolution Medicines Inc. | +0.50 | |
| WLFI | +0.47 | |
| Royalty Pharma Plc Class A | +0.38 | |
| Vertex Pharmaceuticals Incorporated | +0.38 | |
| Charles River Laboratories International Inc. | +0.37 | |
| GPS | +0.36 | |
| VIC | -0.63 | |
| OGN | -0.41 | |
| SAPIEN | -0.37 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
